Calcineurin inhibitors in the treatment of primary focal segmental glomerulosclerosis: a protocol of systematic review and meta-analysis of randomized controlled trials
Focal segmental glomerulosclerosis (FSGS) is a leading cause of kidney diseases worldwide. The prevalence of FSGS, relative to other glomerular disease diagnoses, seems to be increasing worldwide, and it is a major contributor to end-stage renal disease (ESRD). In 2011, McGrogan et al. reported an annual incidence rates of FSGS as 0.2 to 1.8/100, 000 population per year by reviewing literature worldwide
